Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01166698 | Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects | PHASE1 | COMPLETED | 100 | — | — | Aug 1, 2010 | Jan 1, 2011 | Nov 9, 2011 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| AZD9819 | EXPERIMENTAL | Inhaled suspension |
| Placebo | PLACEBO_COMPARATOR | Inhaled suspension |
| Name | Type | Description |
|---|---|---|
| AZD9819 | DRUG | Inhaled single doses of suspension via SPIRA nebuliser |
| Placebo | DRUG | Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B) |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures * Healthy male and female (non-child bearing potential) subjects aged 18 to 50 years with suitable veins for cannulation or repeated venepuncture. * Have a body mass index (BMI) betw...